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Novelty and impact: Metabolic Syndrome (MeS) is linked to increase prostate cancer (PCa) 
aggressiveness by unknown mechanisms. We defined a novel mechanism for PCa progression 
modulation associated to MeS that involved transcription regulation of CLCA2 and miR-196b 
by CTBP1. This protein binds to CLCA2 proximal promoter region and represses its 
transcription together with ZEB1, EP300 and HDACs. Importantly, CLCA2 functions as a PCa 
EMT inhibitor, since it depletion promoted circulating tumor cells (CTCs) dissemination in MeS 
mice.  
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Abstract 
Prostate cancer (PCa) is the most common cancer among men. Metabolic syndrome (MeS) is 
associated with increased PCa aggressiveness and recurrence. Previously, we proposed C-
terminal binding protein 1 (CTBP1), a transcripcional co-repressor, as a molecular link between 
these two conditions. Notably, CTBP1 depletion decreased PCa growth in MeS mice. The aim 
of this study was to investigate the molecular mechanisms that explain the link between MeS 
and PCa mediated by CTBP1. We found that CTBP1 repressed Chloride Channel Accessory 2 
(CLCA2) expression in prostate xenografts developed in MeS animals. CTBP1 bound to CLCA2 
promoter and repressed its transcription and promoter activity in PCa cell lines. Furthermore, 
we found that CTBP1 formed a repressor complex with ZEB1, EP300 and HDACs that 
modulates the CLCA2 promoter activity. CLCA2 promoted PCa cell adhesion inhibiting 
Epithelial-Mesenchymal Transition (EMT) and activating CTNNB1 together with epithelial 
markers (CDH1) induction, and mesenchymal markers (SNAI2 and TWIST1) repression. 
Moreover, CLCA2 depletion in PCa cells injected s.c. in MeS mice increased the Circulating 
Tumor Cells (CTCs) foci compared to control. A miRNA expression microarray from PCa 
xenografts developed in MeS mice, showed 21 miRNAs modulated by CtBP1 involved in 
angiogenesis, extracellular matrix organization, focal adhesion and adherents junctions, among 
others. We found that miR-196b-5p directly targets CLCA2 by cloning CLCA2 3'UTR and 
performing reporter assays. Altogether, we identified a new molecular mechanism for PCa and 
MeS link based on CLCA2 repression by CTBP1 and miR-196b-5p molecules that might act as 
key factors in the progression onset of this disease. 
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INTRODUCTION 
Prostate cancer (PCa) incidence and mortality rates have been declining since 1990. 
Nevertheless PCa is still the most prevalent cancer among men and the second leading cause 
of cancer death
1
. Age, race and family history are the established risk factors for this disease
2
; 
however there is increasing evidence showing that diet and lifestyle play a crucial role in PCa 
biology and tumorigenesis
3–5
.  
Metabolic syndrome (MeS) is a cluster of pathophysiological disorders that comprises increase 
of at least three of the following factors: abdominal obesity, triglycerides, cholesterol, blood 
pressure and glucose
6
. For more than one decade MeS role in PCa incidence and progression 
has been studied with different outcomes; nonetheless recently a meta-analysis revealed that 
this disease is associated with poor PCa patient prognosis, increased tumor aggressiveness and 
biochemical recurrence
7
.  
In the last years our group wondered about the mechanism whereby MeS influences PCa. We 
identified to C-terminal binding protein 1 (CTBP1) as a molecular link among these two 
conditions. CtBP1 is a transcriptional co-repressor of tumor suppressor genes that is activated 
with much higher affinity by NADH (>100-fold) compared to NAD
+8
. Therefore, we generated a 
MeS mice model chronically feeding animals with high fat diet (HFD) and found that CTBP1 
depletion in MeS mice dramatically decreased PCa growth
9,10
.  
Chloride Channel Accessory 2 (CLCA2) is a type I integral transmembrane protein
11
. It was 
proposed as a tumor suppressor in breast and colorectal cancer
12–14
. Tanikawa et al. found that 
CLCA2 expression was remarkably decreased in prostate, breast, bladder, esophageal and lung 
cancers compared to normal tissues. Particularly in PCa, they established that CLCA2 
expression in Prostatic Intraepithelial Neoplasia (PIN) is similar to normal prostate tissue but 
higher than invasive tumors
15
. However, CLCA2 role in PCa has not yet been studied. 
Previously, Elble´s group showed that CLCA2 is a negative regulator of proliferation
16
 and 
epithelial-mesenchymal transition (EMT) in breast cancer (BrCa)
17
. Recently, they reported that 
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CLCA2 is part of two functional adhesion complexes, one with EVA1 and ZO-1, and the other 
with CTNNB1, that are involved in EMT suppression
18
. Also BrCa patients with low CLCA2 
expression in primary tumors have more metastasis
19
. In melanoma, Riker et al. demonstrated 
a negative correlation between a metastatic state and CLCA2 expression
20
. 
Few reports studied the mechanism for CLCA2 expression regulation. So far the most 
important reported inductor is TP53
15,16,21
. On the other hand, epigenetic regulation came out 
as a key factor that represses CLCA2 expression in malignant tissues
13,15
 but how this is 
regulated is not fully understood. 
The aim of this work was to understand CTBP1 role linking MeS with PCa development and 
progression. Hence, we examined CTBP1 function in the regulation of CLCA2 transcription and 
multiple miRNAs using in vitro and in vivo models.  
 
MATERIALS AND METHODS 
Cell culture, transfections and treatments. PC3 (ATCC: CRL-1435), 22Rv1 (ATCC: CRL-2505), 
LNCaP (ATCC: CRL-1740), C4-2 cell lines and its stable derivatives were grown in RPMI 1640 
(Invitrogen) supplemented with 10% of fetal bovine serum and antibiotics in a 5% CO2 
humidified atmosphere at 37°C. PC3.shCTBP1 and its control (PC3.pGIPZ) stable cell lines were 
previously described
9
. The PC3.shCLCA2 (shCLCA2) and its control PC3.pGIPZ (pGIPZ) cells lines 
were generated by lentiviral infection as previously described
9
 using pGIPZ.shCLCA2 or pGIPZ 
plasmids. Stable transfected cells were selected with 2 μg/ml of puromycin (Sigma-Aldrich) for 
10 days and then maintained with puromycin (1 μg/ml). Cells with CtBP1 or CLCA2 over-
expression and its control were generated by transient transfection using polyethylenimine 
(PEI – PolySciences INC) in a PEI:DNA ratio 2:1. Trichostatin A (TSA, Sigma-Adrich) was used 1 
µM for 24 h.  
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Plasmids. CTBP1 plasmid and its control (pcDNA3) were previously described
10
. pGL4 plasmids 
with different lengths of the CLCA2 promoter, pGIPZ.shCLCA2 and pGIPZ control, pLEX-CLCA2 
and pLEX were previously described
16,18
.  
ZEB1 plasmids were previously reported
22
, HDACs plasmids were kindly provided by Dr. Martin 
Monte (Universidad de Buenos Aires, Argentina) and EP300 plasmid was previously 
described
23
.  
The 3’UTR CLCA2 (1,031 bp) was amplified using specific primers (Table I) and cloned in Spe I 
and Hind III restriction sites of pMIR-REPORT firefly luciferase vector plasmid (pMIR, Ambion, 
Grand Island, NY, USA). TOP FLASH plasmid was kindly provides by Jorge Filmus (Sunnybrook 
Health Sciences Centre, Toronto, Canada). Clone was selected by sequencing. Plasmids 
containing miR-196b-5p and miR-196a-5p were kindly provided by Ann-Joy Cheng (Chang Gung 
University, Taiwan)
24
. 
Luciferase reporter assay. PC3 cells were transfected in 12-well plates in triplicate using PEI 
and 1 µg of each plasmid. After 48 h of transfection, luciferase activity was determined by 
Luciferase Assay system (Promega) according to the manufacturer's instructions using 
GloMax® 96 Microplate Luminometer (Promega). Data were normalized to total protein 
determined by Bradford assay. 
RNA isolation and RT-qPCR. Total RNA from cells or xenografts was isolated using TRIReagent 
(Molecular Research Center) followed by an isopropanol precipitation overnight at -20
o
C. 
Retrotranscription (RT) was performed using 2 µg of RNA and RevertAid First Strand kit 
(Fermentas, Vilnius, Lithuania). Real time PCR (qPCR) was performed using TAQ Pegasus 
(Productos Bio-Lógicos, Argentina) in a CFX96 Touch™ Real-Time PCR Detection System (Bio-
Rad). Primers were designed by Primer-BLAST (NIH) and purchased from Macrogen 
(Supplemental Table 1).  
miRNA (100 ng) were retrotranscribed using stem-loop method as previously described
25
. 
Specific stem loop primer for each miRNA was used in RT. Primers for qPCR were the universal 
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reverse primer complementary to the stem loop, and a specific forward primer (Supplemental 
Table 1).  
Chromatin immunoprecipitation (ChIP). ChIP was performed from PC3 cells using anti-CtBP1  
or anti-GAL4 non-specific control antibodies (Santa Cruz Biotechnologies, Santa Cruz, CA, USA), 
as previously described
9
. ChIP-DNA was amplified by qPCR using primers mapping at 1,165 bp 
upstream from CLCA2 transcription start site (TSS), or 200 bp upstream from the HBB TSS 
(Supplemental Table 1). Fold enrichment was calculated normalizing data to input and GAL4. 
Cell adhesion assay. Cell adhesion assay was performed as previously described with some 
modifications
26
. Briefly, after transfections, cells were attached to 96-well plate for 30 min. 
Media was removed and the attached cells were washed twice with PBS, fixed with methanol 
and stained with crystal violet for 10 min. After 2 water washes, stain was dissolved in 10% 
methanol: 5% acetic acid and absorbance at 620 nm was determined with ELISA Multiskan FC 
(Thermo Scientific). 
PCa and MeS mice. Animal model was generated as previously described
9,10
. Briefly, 4 weeks 
old male nu/nu mice (N=24), were randomized into two groups and fed with CD or HFD and 
housed under pathogen free conditions following IBYME’s animal care guidelines. Mice were 
fed ad libitum with CD (3120 kcal/kg, 5% fat, n= 22) or HFD (4520 kcal/kg, 37% fat, n=22) 
generated supplementing chow food with 32% of bovine fat first juice (Fatty, Buenos Aires, 
Argentina). After 12 weeks of diet, each group was randomly divided in two subgroups and s.c. 
injected with PC3.pGIPZ or PC3.shCLCA2 stable cells (4.8 x 10
6
). Body weight was monitored 
once a week and tumor size was measured three times a week. Forty days after injection 
animals were sacrificed and tumors and soft tissues (lung and liver) were excised. Peripheral 
blood was collected by cardiac puncture from each mouse in a tube containing 60 µl of EDTA 
0.5 M.  
Circulating tumor cell (CTC) assay. To recover CTCs from peripheral blood, blood cells were 
obtained by centrifugation and hemolyzed by Ammonium Chloride Potassium (ACK) buffer 
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incubations (3 x 7 min; 1 x 5 min). Cells were washed with PBS and resuspended in RPMI 
medium supplemented with 10 % FBS, antibiotics and puromycin (1 μg/ml). Cells were seeded 
on 12-well plates and medium was replaced every 5 days. After 15 days CTCs were 
photographed with a Q-Color5 Digital Camera (OLYMPUS). 
Microarray Analysis. mRNA microarray was previously reported
9
. RNA obtained from those 
tumors was hybridized with GeneChip miRNA 4.0 (Affymetrix). Data normalization and analysis 
was made as previously described
10
. Microarray data have been deposited in GEO database 
(Accession number: GSE104119). Upregulated miRNAs by CTBP1 with FC>1.5 (p<0.05) and 
signal >5 were selected. Potential miRNA target genes with at least 3 hits, Gene Ontology (GO) 
and pathways analysis were determined using ChemiRs database. 
Statistical analysis. All results are given as mean and standard deviation (SD) of three 
independent experiments unless stated otherwise. Student t-tests or two-way ANOVA 
followed by Tukey test were performed. Shapiro–Wilk and Levene tests were used to assess 
normality and homogeneity of variances. *= p< 0.05; **= p< 0.01;***= p< 0.001. 
 
 
RESULTS 
CTBP1 and MeS repress CLCA2 expression.  
We previously reported a microarray analysis generated from CTBP1-depleted expression or 
control xenografts grown in MeS mice
9
. In this work, we focused our study on the olfactory 
signaling pathway obtained from the microarray Gene Set Enrichment Analysis (GSEA) (Figure 
1A). We found that CTBP1 significantly repressed four genes from this pathway: OR4C45, 
OR5P2, GUCA1C and CLCA2 (Figure 1B). Due to CLCA2 involvement in tumor suppression, we 
further investigated CLCA2 role in PCa and MeS. We first validated microarray results by RT-
qPCR from xenografts generated with PC3.shCTBP1 or control stable cells in CD or HFD fed 
mice. As shown in Figure 1C, we observed CLCA2 induction after CTBP1 depletion in MeS 
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conditions, validating microarrays findings. Next, we determined CLCA2 expression in a panel 
of PCa cell lines (Figure 1D). We found that androgen-sensitive LNCaP cells and the androgen-
insensitive PC3 cells showed higher CLCA2 expression compared to 22Rv1 and C4-2 PCa cells 
lines. 
CTBP1 represses CLCA2 transcription in PC3 cell line.  
To further investigate CLCA2 expression regulation by CTBP1, reporter constructs containing 
different length of CLCA2 promoter regions (-3565 bp to +1 bp from the TSS), were co-
transfected with CTBP1 or control (pcDNA3) plasmids into PC3 cell line. CTBP1 significantly 
repressed the activity of all the different CLCA2 promoter regions (Figure 2A).  The -1182 to +1 
fragment showed the highest CLCA2 promoter activity and it was used in the subsequent 
experiments (Figure 2A). Accordingly to reporter results, we found that CTBP1 repressed 
CLCA2 mRNA levels in PC3 cells (Figure 2B-C). Additionally, using ChIP we determined that 
CTBP1 bound to the CLCA2 proximal promoter region (Figure 2D). Hence, CTBP1 associates to 
CLCA2 promoter and represses its transcription in PCa cell lines. 
CLCA2 is epigenetically regulated by HDACs, ZEB1 and EP300. 
To determine potential transcription factors (TF) that co-regulate with CTBP1 CLCA2 
transcription, we co-transfected CLCA2 reporter with CTBP1 expression plasmid plus a panel of 
TFs selected from the literature that potentially bind to CLCA2 promoter or interacts with 
CtBP1 protein. We found that E2F1, STAT3, RELA and EP300 had no effect on CLCA2 promoter 
activity; however TP53, BRCA1, ETS2 and ZEB1 induced its activity in PC3 cell line (Figure 3A-B 
and Supplemental Figure 1). Moreover, we observed that CLCA2 promoter activity repression 
by CTBP1 was synergistically increased in the presence of EP300 and ZEB1 (Figure 3A-B).  
Furthermore, we assessed HDACs role on CLCA2 transcription regulation by CTBP1. We 
observed that HDAC1 and HDAC2 had no effect on CLCA2 transcription regulation; whereas 
HDAC3, HDAC4 and HDAC6 repressed its activity (Figure 3C-D and Supplemental Figure 1).  
CTBP1 synergistically repressed with HDAC2 and HDAC3 the CLCA2 promoter activity (Figure 
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3C-D). Notably, the HDAC inhibitor, TSA, induced CLCA2 promoter activity and mRNA levels in 
PC3 cells (Figure 3E and F). Altogether these results show for the first time multiple TFs and 
epigenetic co-regulators that modulated CLCA2 gene expression in PCa.  
CLCA2 induces cell adhesion and epithelial phenotype.  
To more deeply understand CLCA2 function in PCa, we generated PCa cells with CLCA2 
depleted or overexpressed and verified its expression (Figure 4A). We next performed cell 
adhesion assays in a panel of PCa cell lines including CLCA2 modulated expression cells. 
Interestingly, CLCA2 over-expression promoted cell adhesion in all PCa cell lines, and CLCA2 
depletion significantly decreased it in PC3 cells (Figure 4B). Hence, CLCA2 plays a role 
increasing cell adhesion, the initial step for invasion and metastasis.  
Based on previous reports
17,18
, we investigated CLCA2 role in EMT and CTNNB pathways 
modulation in PCa. To assess the transcriptional activity of CTNNB we employed TOP FLASH 
reporter plasmid using PC3.shCLCA2 and control (pGIPZ) cells. Interestingly, CLCA2 depletion 
significantly induced CTNNB activation (Figure 4C). In addition, CLCA2 depletion dramatically 
repressed the expression of the epithelial marker CDH1, with concomitant induction of the 
mesenchymal markers expression; SNAI2 and TWIST1, compared to control (Figure 4D). CDH2, 
SNAI1, VIM, ZEB1 and CTNNB did not show expression changes in these conditions (data not 
shown).  
To understand CLCA2 role in PCa associated to MeS, we injected s.c. PC3.shCLCA2 or 
PC3.pGIPZ control cell lines in CD or HFD fed mice. No significant differences were observed in 
tumor volume between CLCA2 depleted and control groups (Supplemental Figure 2). However, 
based on CLCA2 role in PCa cell adhesion and EMT, we selected CTCs from the peripheral 
blood of these mice in a clonogenic assay. We found that CLCA2 depletion increased the 
percentage of mice with CTC foci compared to pGIPZ control mice (Figure 4E). No sign of 
micro- or macro-metastasis were observed in soft tissues (lung and liver) by H&E stains from 
all groups (data not shown). 
Page 10 of 26
John Wiley & Sons, Inc.
International Journal of Cancer
This article is protected by copyright. All rights reserved.
11 
 
Altogether these results propose a novel mechanism for CTBP1 function linking PCa and MeS. 
Thus CTBP1 represses the epithelial gene promoter CLCA2, which in turn, induces 
mesenchymal markers and might promote metastasis.  
CTBP1 regulates multiple miRNAs in PCa associated to MeS.  
To increase the knowledge about the molecular mechanisms for CTBP1 role linking PCa and 
MeS, we assessed miRNAs regulation by CTBP1 in tumors from MeS mice. We hybridized 
miRNA expression microarrays with miRNAs isolated from xenografts described in Figure 1A. 
After data normalization, we obtained 21 miRNAs regulated by CtBP1 (Figure 5A). 
Interestingly, after GO and pathways analysis, we observed that these miRNAs modulated by 
CTBP1 are implicated in angiogenesis, extracellular matrix organization, developmental 
biology, cancer pathways, focal adhesion and adherents junctions among others (Figure 5B-C). 
miR-196b-5p targets CLCA2 and modulates cell adhesion.  
To predict CtBP1 regulated miRNAs that potentially target CLCA2, we performed a supervised 
analysis. From the 21 miRNAs in Figure 5A, we selected the CTBP1-upregulated miRNAs that 
might repress CLCA2 (positive fold change) and determined the predicted target genes using 
ChemiRs (http://omics.biol.ntnu.edu.tw/ChemiRs/). All the miRNAs that have CLCA2 as target 
by at least two databases with different algorithms were selected (Supplemental Table 2, 
column 1 and 2). Seven miRNAs detailed in Supplemental Table 2 (column 3 and 4) were 
analyzed by miRCancer (http://mircancer.ecu.edu/) database. Based on this and literature we 
selected miR-196b-5p as a candidate that targets CLCA2. 
To validate whether miR-196b-5p targets CLCA2 mRNA, we cloned CLCA2 3'UTR region 
downstream of the luciferase gene in a pMIR-REPORT plasmid. We co-transfected CLCA2 
3´UTR and miR-196b, miR-196a or control plasmids in PC3 cells and found that miR-196a and 
miR-196b decreased luciferase activity demonstrating for the first time that CLCA2 is targeted 
by these miRNAs in PCa (Figure 5D).  
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Next, we validated the miRNA microarray result by determining miR-196b-5p expression from 
xenografts generated in MeS or control mice after CtBP1 depletion. Accordingly, CTBP1 
depletion significantly decreased miR-196b-5p expression compared to control only in HFD fed 
mice (Figure 5E). Finally, to understand miR-196b-5p role in PCa, we evaluated its effect on cell 
adhesion. Accordingly, we found that miR-196b decreased cell adhesion compared to control 
or miR-196a, a miRNA with similar sequence but without CLCA2 as a target (Figure 5F). Thus, 
miR-196b-5p emerged as a critical miRNA regulated by CTBP1, suggesting a potential link for 
PCa progression in MeS. 
 
Discussion 
In this work we explored the mechanism underlying CTBP1 role in the modulation of PCa 
progression associated with MeS. We demonstrated that CTBP1 represses CLCA2 in PCa 
xenografts developed in MeS mice. Moreover, we found that CTBP1 binds CLCA2 proximal 
promoter region and represses its transcription together with ZEB1, EP300 and HDACs in PCa 
cell lines. It was previously reported that CTBP1 forms a repressor complex with these co-
regulators
8,27
; nevertheless, we described here for the first time this co-regulation at the CLCA2 
promoter. Epigenetic repression of CLCA2 by gene promoter hypermethylation has already 
been described 
13,15
; however we showed here that CLCA2 is regulated by TSA, highlighting the 
importance of the epigenetic modifications in the CLCA2 expression regulation. In addition, we 
tested a panel of TFs that directly regulated CLCA2: TP53, BRCA1 and ETS2; or TFs that had no 
effect on CLCA2 promoter activity: E2F1, STAT3, RELA and EP300. Overall, our data 
demonstrated novel mechanisms for CLCA2 transcriptional regulation in PCa. 
Regarding CLCA2 function in PCa cells we demonstrated that CLCA2 is an EMT modulator. In 
particular, we showed that CLCA2 promoted cell adhesion, inducing epithelial markers (CDH1) 
and repressing mesenchymal genes (SNAI2 and TWIST1). Notably, CLCA2 depletion 
Page 12 of 26
John Wiley & Sons, Inc.
International Journal of Cancer
This article is protected by copyright. All rights reserved.
13 
 
significantly activated CTNNB TF function. These results are consistent with the reports in BrCa 
that showed CLCA2 promoted an epithelial phenotype by sequestering CTNNB in the 
membrane and, repressing EMT genes
17,18
 (Figure 6). This is the first report showing CLCA2 as 
EMT inhibitor in PCa.  
In this work we also assessed the CLCA2 role in vivo. We found that CLCA2 depleted xenografts 
generated in MeS mice promoted CTCs release in a higher percentage of mice compared to 
CLCA2 control expression xenografts. Although CLCA2 expression modulation did not affect 
PCa growth, these results endorse the idea that CLCA2 loss promotes EMT. Moreover, all these 
findings propose a novel mechanism for CTBP1 oncogenic role through CLCA2 modulation.  
We also described for the first time that CTBP1 modulates multiple miRNAs in PCa from MeS 
mice that are involved in several pathways related to cancer development and progression. 
The importance of miRNAs in PCa has already been widely reported
28
; however there are few 
reports showing miRNA modulation by CTBP1. Indeed, our group demonstrated that CTBP1 
modulates several miRNAs in BrCa
10
, and Chakravarthi and colleagues showed that CTBP1 
modulates the miR-124 in a PCa cell line
29
. Therefore, our results provide a new insight into 
CTBP1 mechanisms leading to tumor progression in PCa. 
Importantly, this is the first report describing miRNAs that target CLCA2 3´UTR in PC3. Based 
on bioinformatic analysis, literature and experimental validation, we selected miRNA-196b-5p 
as an important oncomiR up regulated in several cancers that is involved mainly in metastasis-
related processes
30,31
. In addition, it was recently reported that miRNA-196b-3p 
overexpression promoted tumor development in castration resistant PCa mice
32
. Here, we 
found that the miR-196b-5p is induced by CTBP1 in tumors from MeS mice, targets CLCA2 and 
inhibits cell adhesion. Although miR-196a is also targeting CLCA2, this miRNA was not regulate 
by CTBP1 and also it did not regulated cell adhesion.  
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In summary, we defined a mechanism for CTBP1 oncogenic role in PCa associated with MeS, 
which involves CLCA2 and miR-196b-5p (see hypothetical model Figure 6). More studies are 
necessary to establish CLCA2 and miR-196b-5p as biomarker candidates for these diseases.  
 
FIGURE TO LEGENDS  
Figure 1. CtBP1 and MeS repress CLCA2. A) Gene Set Enrichment Analysis (GSEA) plot from 
olfactory signaling pathway. B) Microarray relative expression levels from OR4C45, OR5P2, 
GUCA1C and CLCA2. C) CLCA2 RT-qPCR from xenografts with CTBP1 depleted (shCtBP1) or 
control (pGIPZ) expression generated in HFD or CD fed mice. D) CLCA2 mRNA levels in PCa cell 
lines measured by RT-qPCR. 
Figure 2. CTBP1 represses CLCA2 transcription in PC3 cell line. A) Plasmids with different 
length of the CLCA2 promoter were co-transfected with CTBP1 or control (pcDNA3) plasmids in 
PC3 cells and Luciferase activity was determined. Bars indicate mean and SD of two 
independent experiments with three replicates. B) CLCA2 expression levels by RT-qPCR from 
PC3 cells after CTBP1 plasmid transfection or C) from PC3.pGIPZ and PC3.shCTBP1 stable cell 
lines. D) ChIP analysis using CTBP1 or non-specific (GAL4) antibodies was performed. DNA-ChIP 
was analyzed by qPCR using primers located at the CLCA2 proximal promoter region or a non-
specific region (HBB). Fold enrichment was calculated normalizing data to input and GAL4. 
Figure 3. CLCA2 is epigenetically regulated by HDACs, ZEB1 and EP300. A-D) PC3 cells were co-
transfected with the CLCA2 promoter reporter (-1182/+1) and CTBP1 or control (pcDNA3) 
plasmids plus ZEB1, EP300, HDAC2 or HDAC3, and Luciferase activity was determined. The 
mean of two independent experiments with three replicates and SD is plotted. E) PC3 cells 
were exposed to TSA (1 µM) and co-transfected with CLCA2 promoter reporter (-1182/+1) and 
Luficerase activity was determined. F) mRNA CLCA2 levels measured by RT-qPCR of PC3 cells 
treated with TSA 1 µM. 
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Figure 4. CLCA2 induces cell adhesion and epithelial phenotype. A) CLCA2 mRNA expression 
levels by RT-qPCR from PC3 cells after CLCA2 plasmid transfection or from PC3.pGIPZ and 
PC3.shCLCA2 stable cell lines B) Cell adhesion assay in CLCA2 depleted (shCLCA2) or 
overexpressed cells. C) PC3.pGIPZ or PC3.shCLCA2 stable cells lines were transfected with TOP 
FLASH plasmid and Luficerase activity was determined. The mean of a representative 
experiment with three replicates and SD is plotted. D) CDH1, SNAI2, TWIST1 gene expression 
from PC3.shCLCA2 cells measured by RT-qPCR. E) Percentage of mice with or without CTCs is 
shown.  The mice were fed with CD or HFD and s.c. injected with PC3.shCLCA2 or control 
(pGIPZ) stable cell lines. Number of CTCs was calculated as the number of cells obtained from 
the blood with the capability to make a colony in a plate. Representative CTCs foci picture from 
CD or HFD peripheral blood mice after s.c. injection with PC3.shCLCA2 or control (pGIPZ) stable 
cell lines. 
Figure 5. CLCA2 repression by CtBP1 is mediated by miR-196b-5p. A) miRNAs modulated by 
CTBP1 from xenograft generated in MeS mice. miR-196b-5c that is used in the following 
experiments is shadow. B) GO terms and (C) pathways for the targets of the miRNAs up 
regulated or down regulated by CTBP1 identified by ChemiR database. D) PC3 cells were co-
transfected with 3’ UTR CLCA2 plasmid and miR-196a, miR-196b or its control (pcDNA3). 
Luciferase activity was determined. E) miR-196b-5p expression levels from CTBP1 depleted or 
control xenografts generated in HFD or CD fed mice measured by miRNA RT-qPCR. F) Cell 
adhesion in PC3 cells transfected with pcDNA3 (control), miR-196a or miR-196b expression 
plasmids. 
Figure 6. Hypothetical model. CtBP1 protein assembles to CLCA2 proximal promoter region 
together with p300, ZEB1, HDAC2 and HDAC3, and represses its transcription. In addition, 
CtBP1 induces miR-196b-5p which, in turn represses CLCA2 expression. Hence, CLCA2 
promotes an epithelial phenotype by sequestering CTNNB in the membrane and repressing 
EMT genes. 
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